Articles tagged "Rejection"

2022 American Transplant Congress
Dd-cfdna Correlates With Acute Rejection In The Setting Of Bk Viremia After Kidney Transplantation
N. M. Ali¹, J. Miles², V. Tatapudi¹, R. Chand¹, R. Montgomery¹
¹NYU Langone Transplant Institute, New York, NY, ²CareDx, Brooklyn, NY
*Purpose: BK virus reactivation is common among kidney transplant recipients (KTRs) and is a risk factor for allograft loss. Currently, there is no clearly established…
2022 American Transplant Congress
Single Cell Multiomics Reveals Immune Mediators in Acute Cellular Rejection Following Pediatric Liver Transplantation
B. Rocque¹, D. Sarode², A. Barbetta³, P. Singh⁴, C. Goldbeck⁴, C. Weaver⁵, O. Akbari⁴, R. Kohli⁵, J. Emamaullee⁶
¹University of Southern California Keck School of Medicine, Los Angeles, CA, ²Keck School of Medicine of University of Southern California, Pasadena, CA, ³Surgery, abdominal transplat, University of Southern California, Los Angeles, CA, ⁴Keck School of Medicine of USC, Los Angeles, CA, ⁵Childrens Hospital Los Angeles, Los Angeles, CA, ⁶University of Southern California, Los Angeles, CA
*Purpose: Acute cellular rejection (ACR) is a common complication following pediatric liver transplantation with potential negative effects on allograft longevity. Currently, diagnosis and management are…
2022 American Transplant Congress
Histologic Borderline Reflects Molecular Injury Not Rejection: Results from the Trifecta Study
P. F. Halloran¹, K. S. Madill-Thomsen¹, Z. Demko², A. Prewett², P. Billings², P. Gauthier², .. and the Trifecta Investigators³
¹Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, ²Natera Inc., San Carlos, CA, ³., ., AB, Canada
*Purpose: In the Trifecta study (NCT04239703), we recently compared indication biopsy diagnoses (MMDx and histology) and plasma %dd-cfDNA levels for indication biopsies (JASN in press…
2022 American Transplant Congress
Differential Impact of Subclinical Kidney Transplant Rejection in Young Adults
S. Raza¹, G. Agarwal¹, H. Fatima¹, R. Gaston¹, V. Hauptfeld-Dolesjek¹, B. Julian¹, C. Kew¹, V. Kumar¹, S. Mehta¹, S. Ong¹, F. Rosenblum¹, G. Towns¹, R. Mannon², M. Seifert¹
¹School of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²College of Medicine, University of Nebraska, Omaha, NE
*Purpose: Serum creatinine, while an insensitive biomarker of allograft injury, is the current standard for assessing the stability of allograft function and guiding kidney transplant…
2022 American Transplant Congress
Donor-Derived Cell-Free DNA Trends Before and After Rejection Vary Based on Timing of Rejection
C. Rebello¹, K. Guo¹, S. Park², B. Kinsella¹, L. Zhao¹, J. Friedewald¹
¹Northwestern University, Chicago, IL, ²Transplant Nephrology, Northwestern University, Chicago, IL
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) has been used for acute rejection detection and trending levels may help predict future rejection and assess the adequacy of…
2022 American Transplant Congress
Detection of Early Graft Injury After Liver Transplantation with Blood-Bile Ratio of Tacrolimus: The TUBE Trial
M. M. Pascale¹, G. Bianco¹, L. Ferri¹, F. Giovinazzo¹, A. Liguori², G. Marrone², A. Grieco², S. Agnes¹
¹General Surgery and Liver Transplant Unit, Fondazione IRCSS - Policlinico "A. Gemelli", Roma, Italy, ²Transplant Hepatology Unit, Fondazione IRCSS - Policlinico "A. Gemelli", Roma, Italy
*Purpose: The aim of the“Tacrolimus in Bile”(TUBE)Trial is the creation of a laboratory parameter for the early detection of hepatic injury after liver transplant.*Methods: TUBE…
2022 American Transplant Congress
Infections Following Rejection Therapies in Solid Organ Transplant Recipients
S. Gupta¹, J. Gea-Banacloche², H. Me³, D. M. Chascsa⁴, H. R. Vikram², R. Yaman¹, L. Kodali³
¹Internal Medicine, Mayo Clinic, Scottsdale, AZ, ²Infectious Diseases, Mayo Clinic, Phoenix, AZ, ³Transplant Nephrology, Mayo Clinic, Phoenix, AZ, ⁴Hepatology, Mayo Clinic, Phoenix, AZ
*Purpose: Infections are known complications of solid-organ transplant. They are most prevalent in the first 12 months after transplant when immunosuppression is at its peak.…
2022 American Transplant Congress
Establishment And Validation Of A Predictive Model For Differential Rejection Diagnosis By Gene Expression Profiling (GEP) In Renal Allograft Biopsies Using Banff Human Organ Transplant (B-HOT) Gene Panel
H. Zhang¹, R. Haun², F. Collin¹, C. Cassol², S. Coley², J. Wilson², S. Stone¹, K. Qu¹, W. Tian¹, N. Agrawal¹, G. Shekhtman¹, C. Larsen²
¹CareDx, Inc., Brisbane, CA, ²Arkana Laboratories, Little Rock, AR
*Purpose: Large scale GEP studies evaluating the performance of Banff-endorsed B-HOT gene panel for allograft rejection diagnosis have not been published. In this study, we…
2022 American Transplant Congress
An Initial Analysis of Baseline Levels of Dd-cfdna After Pancreas Transplantation: A Prospective Study from High-Volume Centers in the United States
A. Yoo¹, I. Qian¹, A. Riedel¹, G. Kibria¹, A. Bartosic¹, R. Soltani², O. Nduanya³, M. Omidi³, J. S. Odorico², P. L. Abrams³, M. Cooper³, J. S. Bromberg¹, J. R. Scalea¹
¹University of Maryland School of Medicine, Baltimore, MD, ²University of Wisconsin School of Medicine, Madison, WI, ³Georgetown University School of Medicine, Washington, DC
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) testing, which has been validated for monitoring kidney transplant (KTx) rejection, may provide an alternative to pancreas biopsy that prevents…
2022 American Transplant Congress
Nivolumab After Sorafenib Failure in Liver Recipients with HCC Recurrence
J. Kwon
Surgery, Samsung Medical Center, Seoul, Korea, Republic of
*Purpose: Several treatments have recently been known for hepatocellcular carcinoma (HCC) who have failed to treat sorafenib. Immune checkpoint inhibitors have proven to be effective,…